SNY (Sanofi) stock is in for a key growth catalyst

In the latest session, Sanofi (NASDAQ: SNY) closed at $45.05 up 0.69% from its previous closing price of $44.74. In other words, the price has increased by $+0.31 from its previous closing price. On the day, 2757560 shares were traded. SNY stock price reached its highest trading level at $45.10 during the session, while it also had its lowest trading level at $44.70.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

For a deeper understanding of Sanofi’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.30. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.26.

Upgrades & Downgrades

Valuation Measures:

As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.10, and their Forward P/E ratio for the next fiscal year is 10.07. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.45 while its Price-to-Book (P/B) ratio in mrq is 1.59.

Stock Price History:

Over the past 52 weeks, SNY has reached a high of $57.79, while it has fallen to a 52-week low of $36.91. The 50-Day Moving Average of the stock is 41.04, while the 200-Day Moving Average is calculated to be 48.01.

Shares Statistics:

For the past three months, SNY has traded an average of 2.93M shares per day and 2.8M over the past ten days. A total of 2.50B shares are outstanding, with a floating share count of 2.26B. Insiders hold about 16.40% of the company’s shares, while institutions hold 10.30% stake in the company. Shares short for SNY as of Oct 13, 2022 were 4.95M with a Short Ratio of 5.31M, compared to 3.91M on Sep 14, 2022.

Dividends & Splits

According to the company, the forward annual dividend rate for SNY is 1.75, from 3.20 in the trailing year. Against a Trailing Annual Dividend Yield of 7.15%, it implies a Forward Annual Dividend Yield of 4.23%. The stock’s 5-year Average Dividend Yield is 3.85. The current Payout Ratio is 0.00% for SNY, which recently paid a dividend on Jun 26, 2022 with an ex-dividend date of May 25, 2022. Stock splits for the company last occurred on Sep 29, 2013 when the company split stock in a 5:1 ratio.

Earnings Estimates

There are 1 different market analysts currently analyzing its stock. On average, analysts expect EPS of $1.34 for the current quarter, with a high estimate of $1.34 and a low estimate of $1.34, while EPS last year was $1.28. The consensus estimate for the next quarter is $0.87, with high estimates of $0.87 and low estimates of $0.87.

Analysts are recommending an EPS of between $4.35 and $4.25 for the fiscal current year, implying an average EPS of $4.3. EPS for the following year is $4.41, with 3 analysts recommending between $4.7 and $4.1.

Revenue Estimates

A total of 3 analysts believe the company’s revenue will be $11.5B this quarter.It ranges from a high estimate of $11.62B to a low estimate of $11.35B. As of the current estimate, Sanofi’s year-ago sales were $11.85B, an estimated decrease of -2.90% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $10.78B, a decrease of -5.60% less than the figure of -$2.90% in the same quarter last year. There is a high estimate of $10.87B for the next quarter, whereas the lowest estimate is $10.64B.

A total of 4 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $42.05B, while the lowest revenue estimate was $41.19B, resulting in an average revenue estimate of $41.54B. In the same quarter a year ago, actual revenue was $44.63B, down -6.90% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $43.55B in the next fiscal year. The high estimate is $44.94B and the low estimate is $42.37B. The average revenue growth estimate for next year is up 4.80% from the average revenue estimate for this year.